Reports on heart failure mortality during the past several years show that it’s on the rise more recently compared to declines, but a research letter released Wednesday in JAMA Cardiology blames the ...

Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.

The COVID pandemic didn’t just kill people directly. It appears to have accelerated a long-brewing reversal in U.S. heart failure deaths, with mortality climbing faster since 2020 after years of ...

Frailty after kidney transplantation is a harbinger for death and other major adverse outcomes in hospitalized patients. The hospital frailty risk score (HFRS) predicts graft failure, severe infection ...